COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022

This work evaluated neutralising antibody titres against wild type (WT) SARS-CoV-2 and four Omicron variants (BA.1, BA.2, BA.4 and BA.5) in healthcare workers who had breakthrough BA.1 infection. Omicron breakthrough infection in individuals vaccinated three or four times before infection resulted i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kliker, Limor, Zuckerman, Neta, Atari, Nofar, Barda, Noam, Gilboa, Mayan, Nemet, Ital, Abd Elkader, Bayan, Fratty, Ilana S, Jaber, Hanaa, Mendelson, Ella, Alroy-Preis, Sharon, Kreiss, Yitshak, Regev-Yochay, Gili, Mandelboim, Michal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2022
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336169/
https://www.ncbi.nlm.nih.gov/pubmed/35904058
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.30.2200559
Descripción
Sumario:This work evaluated neutralising antibody titres against wild type (WT) SARS-CoV-2 and four Omicron variants (BA.1, BA.2, BA.4 and BA.5) in healthcare workers who had breakthrough BA.1 infection. Omicron breakthrough infection in individuals vaccinated three or four times before infection resulted in increased neutralising antibodies against the WT virus. The fourth vaccine dose did not further improve the neutralising efficiency over the third dose against all Omicron variants, especially BA.4 and BA.5. An Omicron-specific vaccine may be indicated.

Ejemplares similares